Skip to content

EV / sales at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
ALN
Alnylam PharmaceuticalsALNY
9.9×-4.7×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
10.7×-12.1×
Royalty Pharma logo
Royalty PharmaRPRX
11.9×+3.0×
AbbVie logo
AbbVieABBV
7.5×+1.0×

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

Based on the most recent quarter.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's EV / sales?
Arrowhead Research (ARWR) reported EV / sales of 14× in Q1 2026.
How has Arrowhead Research's EV / sales changed year-over-year?
Arrowhead Research's EV / sales increased by 354.4% year-over-year, from 3.1× to 14×.
What is the long-term trend for Arrowhead Research's EV / sales?
Over 5 years (2020 to 2025), Arrowhead Research's EV / sales has grown at a -35.4% compound annual growth rate (CAGR), from 49.8× to 5.6×.
What does EV / sales mean?
What the whole business costs relative to its annual sales.
How do you interpret EV / sales?
A fallback valuation gauge for pre-profit or cyclical firms. Like P/S, only comparable across similar-margin businesses, but it accounts for debt and cash unlike P/S.
How does EV / sales compare across companies?
Compare within a margin cohort; the debt-and-cash adjustment makes it cleaner than P/S for leveraged firms.